An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
Incyte Corporation
Sellas Life Sciences Group
Pfizer
MacroGenics
Celgene
AbbVie
Novartis
INSYS Therapeutics Inc
Novartis